2018
Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial
Powles RL, Redmond D, Sotiriou C, Loi S, Fumagalli D, Nuciforo P, Harbeck N, de Azambuja E, Sarp S, Di Cosimo S, Huober J, Baselga J, Piccart-Gebhart M, Elemento O, Pusztai L, Hatzis C. Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial. JAMA Oncology 2018, 4: e181564-e181564. PMID: 29902299, PMCID: PMC6224305, DOI: 10.1001/jamaoncol.2018.1564.Peer-Reviewed Original ResearchConceptsDual HER2 blockadeImmune gene signaturesPathologic complete responseDual HER2HER2 blockadeNeoALTTO trialDual anti-HER2 blockadeHigher immune gene expressionTrastuzumab Treatment Optimisation (ALTTO) trialHER2-positive breast cancerGene signatureAnti-HER2 blockadeHigher useHER2-positive patientsMultivariable logistic regressionRandomized clinical trialsGood responseHigh rateImmune gene expressionNeoadjuvant lapatinibTherapy armIdentifies patientsNeoadjuvant therapyComplete responseGene expression signatures
2017
New Therapeutic Strategies for Triple-Negative Breast Cancer.
Székely B, Silber AL, Pusztai L. New Therapeutic Strategies for Triple-Negative Breast Cancer. Oncology 2017, 31: 130-7. PMID: 28205193.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerResidual cancerBreast cancerEarly-stage triple-negative breast cancerUnselected triple negative breast cancerIntroduction of taxanesOngoing adjuvant trialsImmune checkpoint inhibitorsSurvival of patientsImportant clinical trialsImportant therapeutic advanceBRCA-mutant cancersNew therapeutic strategiesAntibody-drug conjugatesAdjuvant trialsNeoadjuvant chemotherapyAdjuvant therapyCheckpoint inhibitorsIdentifies patientsTherapeutic advancesClinical trialsHigh riskTherapeutic strategiesCancerTrials